EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische Studie

First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer

John V Heymach, Noboru Yamamoto, Nicolas Girard, Gerrina Ruiter, Egbert F Smit, David Planchard, Ernest Nadal, Yi-Long Wu, Jon Zugazagoitia, Hai-Yan Tu, Christina S Baik, Kiyotaka Yoh und 13 weitere

New England Journal of Medicine · 30.04.2026 · 394 (17) · 1675-1684

DOI: 10.1056/nejmoa2516969 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 30.04.2026. Verfasst von John V Heymach und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston. Hauptthemen laut MEDLINE: Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Erb-b2 Receptor Tyrosine Kinases, Lung Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsCarcinoma, Non-Small-Cell LungErb-b2 Receptor Tyrosine KinasesLung NeoplasmsTyrosine Kinase InhibitorsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAcrylamidesImidazolesMutationProgression-Free SurvivalPyrimidines

Substanzen

AcrylamidesErb-b2 Receptor Tyrosine KinasesERBB2 protein, humanImidazolesPyrimidinesTyrosine Kinase Inhibitorszongertinib

Autor:innen und Institutionen

  • Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston.
  • Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo.
  • Institut Curie, Institut du Thorax Curie-Montsouris, Paris.
  • Paris-Saclay University, Université de Versailles Saint-Quentin-en-Yvelines, Versailles, France.
  • Department of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam.
  • Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam.

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Heymach, J. V., Yamamoto, N., Girard, N., Ruiter, G., Smit, E. F., Planchard, D., Nadal, E., Wu, Y. L., Zugazagoitia, J., Tu, H. Y., Baik, C. S., Yoh, K., Soo, R. A., Zhao, Y., Sabari, J. K., Wermke, M., Scheffler, M., Ahn, M. J., Fernamberg, K., …, & Beamion LUNG-1 Investigators (2026). First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer. New England Journal of Medicine, 394(17), 1675-1684. https://doi.org/10.1056/nejmoa2516969

Vancouver

Heymach JV, Yamamoto N, Girard N, Ruiter G, Smit EF, Planchard D, et al. First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2026;394(17):1675-1684. doi:10.1056/nejmoa2516969

BibTeX
@article{Heymach2026,
  author = {Heymach, John V and Yamamoto, Noboru and Girard, Nicolas and Ruiter, Gerrina and Smit, Egbert F and Planchard, David and Nadal, Ernest and Wu, Yi-Long and Zugazagoitia, Jon and Tu, Hai-Yan and Baik, Christina S and Yoh, Kiyotaka and Soo, Ross A and Zhao, Yanqiu and Sabari, Joshua K and Wermke, Martin and Scheffler, Matthias and Ahn, Myung-Ju and Fernamberg, Kristie and Schroeter, Lukas and Sadrolhefazi, Behbood and Thamer, Claus and Eigenbrod-Giese, Sabina and Popat, Sanjay and Beamion LUNG-1 Investigators, Beamion LUNG-1 Investigators},
  title = {First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {17},
  pages = {1675--1684},
  doi = {10.1056/nejmoa2516969}
}
Kostenlos starten →